Magnesium Chloride increases apoptosis and decreases prostate cancer cells migration

Julianna Maria Santos¹; Fazle Hussain²*

Texas Tech University, Mechanical Engineering Department (TTU), Internal Medicine, and Cell Physiology and Molecular Biophysics (TTUHSC), Lubbock, Texas, USA

Corresponding Author: Fazle Hussain, Texas Tech University, Mechanical Engineering Department (TTU), Internal Medicine, and Cell Physiology and Molecular Biophysics (TTUHSC), Lubbock, Texas, USA

Submission Date: June 10th, 2017, Acceptance Date: January 27th, 2017, Publication Date: January 31st, 2017

Citation: Santos J.M., Hussain F., Magnesium Chloride increases apoptosis and decreases prostate cancer cells migration. Functional Foods in Health and Disease 2018; 8(1): 62-78

ABSTRACT

Background: Reduced levels of magnesium can cause several diseases and increase cancer risk. Motivated by magnesium chloride’s (MgCl2) non-toxicity, physiological importance, and beneficial clinical applications, we studied its action mechanism and possible mechanical, molecular, and physiological effects in prostate cancer with different metastatic potentials.

Methods: We examined the effects of MgCl2, after 24 and 48 hours, on apoptosis, cell migration, expression of epithelial mesenchymal transition (EMT) markers, and V-H⁺-ATPase, myosin II (NMII) and the transcription factor NF Kappa B (NFkB) expressions.

Results: MgCl2 induces apoptosis, and significantly decreases migration speed in cancer cells with different metastatic potentials. MgCl2 reduces the expression of V-H⁺-ATPase and myosin II that facilitates invasion and metastasis, suppresses the expression of vimentin and increases expression of E-cadherin, suggesting a role of MgCl2 in reversing the EMT. MgCl2 also significantly increases the chromatin condensation and decreases NFkB expression.

Conclusions: These results suggest a promising preventive and therapeutic role of MgCl2 for prostate cancer. Further studies should explore extending MgCl2 therapy to in vivo studies and other cancer types.

Keywords: Magnesium chloride, prostate cancer, migration speed, V-H⁺-ATPase, and EMT.
BACKGROUND
Magnesium (Mg\(^{2+}\)) is the fourth most common cation in the human body, and it has a crucial role as a co-factor in more than 300 enzymatic reactions related to energy metabolism and nucleic acid synthesis [1, 2]. Mg\(^{2+}\) is also involved in several physiological processes such as hormone receptor binding, gating of calcium channels, transmembrane ion flux, muscle contraction, neuronal activity, vasomotor tone control, cardiac excitability, and neurotransmitter release. Diet and lifestyles significantly impact the risk factors associated with prostate cancer [2] and can greatly arrest cancer progression [3]. Studies have shown the benefits of Mg\(^{2+}\) supplementation for several medical conditions such as eclampsia, preeclampsia, arrhythmia, severe asthma, and migraine. Furthermore, there are beneficial results such as improved glucose and insulin metabolism, alleviated dysmenorrhea, and leg cramps in women [1, 4]. Chronic low levels of Mg\(^{2+}\) are associated with several severe diseases, including diabetes, hypertension, coronary heart disease, and osteoporosis [1, 5]. Mg\(^{2+}\) homeostasis is usually maintained by renal regulation of Mg\(^{2+}\) reabsorption, although the exact mechanism of this regulation is not understood [1]. Cisplatin treatment has the side effect of inducing Mg\(^{2+}\) deficiency that enhances nephrotoxicity [6]. As a result, Mg\(^{2+}\) supplementation improves the adverse effects of cisplatin and decreases renal toxicity in cancer patients treated with cisplatin (by causing significant changes in plasma creatinine and urea levels) [7]. Epidemiologic studies have shown that Mg\(^{2+}\) intake may decrease the risk of colorectal cancer (CRC), although this observation is not universal [8].

Cancer cells are known to over-regulate many proteins (such as V-H\(^{+}\)-ATPase) that enhance their metastatic potentials and facilitate invasion of neighboring tissues and launch metastasis. V-H\(^{+}\)-ATPase on the cancer cell plasma membrane acidifies the extracellular environment by extruding protons which activates metalloproteinases that digest the extracellular matrix to promote invasion and metastasis [9, 10]. Because of epithelial mesenchymal transition (EMT), the marker vimentin is over-regulated while F-actin and E-Cadherin are down-regulated. EMT, a reversible process that causes changes in cell shape, behavior, and motility, may facilitate cancer metastasis [11–15]. EMT usually occurs in embryo formation, wound healing, and malignant transformation [16].

Prostate adenocarcinoma is the most common male cancer in the United States, with 1 in every 4 newly diagnosed cancers belonging to this category [17]. The cause and progression of prostate cancer are not well understood; the poor prognosis of prostate carcinoma is widely recognized [18]. We used prostate cancer as an experimental model due to its high incidence and lethality [17]. The therapeutic effect of MgCl\(_2\) in cancer cells is underexplored, with the action mechanism remaining unknown. So far, only one recent study demonstrated increased apoptosis induced by treatment with MgCl\(_2\) in one specific prostate cancer cell line [2].

We discovered MgCl\(_2\) can be an effective preventive therapeutic agent for prostate cancer because of its effect in decreasing cell growth and migration via down-regulating V-H\(^{+}\)-ATPase, in addition to reversing the EMT process via decreasing vimentin expression and increasing F-actin and E-Cadherin. Furthermore, MgCl\(_2\) shows beneficial effects in several diseases besides cancer. Further studies are required to understand the action mechanism of MgCl\(_2\) and establish the relevant metabolic pathways.
METHODS

Cell Lines and Culture

All cells were cultured at 37°C in a 5% CO₂ environment. Prostate cancer cells (LNCaP, DU145, CL2, and PC3) were provided by Dr. Stephanie Filleur (Texas Tech University Health Sciences Center, Lubbock, TX). Cells were cultured in RPMI 1640 medium with L-glutamine (Gibco, 10-040-CV, Thermo Fisher Scientific, Massachusetts, USA), supplemented with 5% fetal bovine serum (FBS) (Gibco, 10437-028, Thermo Fisher Scientific, Massachusetts, USA). LNCaP cells had an additional supplement of 1% penicillin-streptomycin antibiotics (Gibco, 15140-122). For every passage, cells were harvested using trypsin for 2 minutes (Gibco by Life Technologies, 25302-062 - 5ml per flask) at 37°C for DU145, CL2, and PC3, and 1 minute for LNCaP. Trypsin was inhibited by adding 500 µl FBS, and then cells were placed in a conic tube and centrifuged for 5 minutes at 1000 rpm (Eppendorf Centrifuge 5804R, Hauppauge, New York, USA). The supernatant was removed, and cells were suspended in 2-4 ml fresh medium and counted with trypan blue (Corning, 25900CI, New York, USA) using an automated cell counter (TC20, Bio-Rad, Berkeley, California, USA). LNCaP cells are lowly metastatic and have androgen receptors and low rates of growth [19]. DU145, a moderately metastatic cell line that does not express androgen receptors, was obtained from a brain metastasis [20]. CL2 is a LNCaP parental, has a highly metastatic phenotype, and is androgen receptor insensitive [19, 21]. PC3 is a highly metastatic cell line that does not express androgen receptors [21] and was obtained from a bone metastasis [22].

Cell Viability Assay

Cells were plated in a 12 well plate until sub-confluent and then treated with 500 µM MgCl₂ in culture medium (Sigma-Aldrich, M4880) for 48 hours. Control cells were grown in culture medium. After 48 hours, the medium was removed from the wells and 100 µl annexin V binding buffer was added (422201, BioLegend, California, USA) along with the stain annexin V alexa fluor 488 (Invitrogen by Life Technologies, A13201, Carlsbad, California, USA, 5 µl in 100 µl buffer). Cells were incubated for 15 minutes at room temperature. Next, the stain was removed and 100 µl annexin V binding buffer was added. Images were acquired with a Nikon Eclipse motorized microscope (Nikon Instruments Inc., New York, USA) using GFP filter (488nm). Magnification 20x.

Monolayer Wound Scratch Assay

Cells were seeded in a 12 well plate. After total confluence, a wound was made in each well using a 10 µl pipette tip [23]. The medium was removed, cells rinsed with DPBS (Corning, 21-031-CV) to remove debris, and a fresh medium containing 5% FBS was added. MgCl₂ was added to culture medium at concentrations of 25 µM, 50 µM, 200 µM, 500 µM, and 1 mM. The wound scratch assay was imaged every 10 minutes for 24 hours using a Nikon Eclipse motorized microscope with an incubator at 5% CO₂ and 37°C. The migration speed was calculated by subtracting the initial from the final wound widths and dividing by the elapsed time.
Subcellular Fractionation

Prostate cells were trypsinized, washed twice with cold PBS, and resuspended in 3 ml of homogenizer buffer containing 1.3 M sucrose (Sigma-Aldrich S7030, St. Louis, Missouri, USA), 1 mM MgCl₂ (Sigma-Aldrich, M4880), and 10 mM potassium phosphate buffer pH 6.8 (Sigma-Aldrich, P5379) supplemented with a protease inhibitor cocktail (ThermoFisher Scientific, 88265) at a concentration of one tablet per 50 ml. Cells were homogenized 20 times in a Teflon/glass dounce homogenizer. The suspension was then stored as a homogenate fraction (containing all cellular fractions including plasma membrane, cytosol, and nucleus) at -80°C. The protein concentration was determined with a spectrophotometer/fluorometer (DeNovix, DS-11 FX+, Wilmington, Delaware, USA) using the nano drop function at 280 nm prior to performing western blots.

Fluorescence Staining

Cells were plated on coverslips until sub-confluence reached and then treated with 500 µM MgCl₂ for 48 hours. Control cells were maintained in just the cell culture medium. After 48 hours, cells were fixed with 4% paraformaldehyde, quenched with Phosphate Buffer Saline (PBS) with 50 mM NH₄Cl (Sigma-Aldrich, 213330) for 10 minutes, permeabilized with 0.1% PBS-Triton for 10 minutes, blocked with 1% PBS-BSA (Sigma-Aldrich, A2153) for 15 minutes, and incubated for 1 hour with alexa fluoro phalloidin 488 (dilution 1:300 in PBS-BSA, Molecular probes by Life Technologies A12379, Eugene, Oregon) that specifically stains F-actin (filaments). After staining, the coverslips were washed 7 times with PBS and mounted on glass slides using Prolong Gold antifade reagent with the nuclear stain DAPI (Molecular probes by Life Technologies, P36935). Images were obtained at 90x using a Nikon Eclipse motorized microscope.

Western Blots

Homogenate fractions (30 µg protein), the control, and samples treated with MgCl₂ (500 µM), were diluted 1:1 in laemmlı sample buffer (Bio-Rad, 161-0737) with 50 µl 2-mercaptoethanol (Bio-Rad, 161-0710), placed in 4-20% gradient acrylamide gels (Bio-Rad, 456-8093), and separated by electrophoresis. Samples from the gels were transferred to nitrocellulose membranes (Bio-Rad, 170-4158) using the Trans-Blot system (Bio-Rad, 170-4155). Membranes were incubated for 1 hour in a 3% milk, Phosphate Buffer Saline (PBS), and Tween solution on a plate shaker (blocked). The blocking solution was made from 3 g of milk powder (Nestle, nonfat dry milk, Glendale, California, USA), dissolved in 100 ml of PBS with Tween. PBS was prepared by mixing (for each liter) KCl 2.7 mM (Sigma-Aldrich, P3911), KH₂PO₄ 1.47 mM (Sigma-Aldrich, P5379), Na₂HPO₄ 8.1 mM (Sigma-Aldrich, S9763), and NaCl 137 mM (Fisher Chemical, S641-212). Tween was added to PBS (Bio-Rad, 170-6531, 1:1000 dilution) at the time of the experiment. Then membranes were incubated with primary antibodies for V-H⁺-ATPase c subunit (Developmental Studies Hybridoma Bank, 224-256-2-s, dilution 1:100), myosin II (NMIIB) (Developmental Studies Hybridoma Bank, CMII23, dilution 1:500), vimentin (Developmental Studies Hybridoma Bank, AMF-17b-s, dilution 1:300), E-Cadherin (Cell Signaling, #14472, Beverly, Massachusetts - dilution 1:1000), and transcription factor NFkB (Developmental Studies Hybridoma Bank, PRCP-NFkB1-2B9, dilution 1:300) for 2
hours at 37°C. β-actin was used as loading control (Sigma-Aldrich, A3854 -dilution 1:25000). Membranes were washed 2 times in the PBS-Tween solution for 5 minutes. Finally, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies anti-mouse IgG (JacksonImmuno Research,115035068, West Grove, Pennsylvania) and anti-rabbit IgG (JacksonImmuno Research,111036003, dilution for secondary antibodies 1:1000) for 1 hour at 37°C. The blots were revealed using ECL solution (Bio-Rad,170-5060) and visualized using an image analyzer system (Bio-Rad,ChemiDocMP, 1708265). Expression levels were quantified using ImageJ software. All blots were normalized from the loading β-actin control.

RESULTS

MgCl₂ Induces Apoptosis.
To address if MgCl₂ (500 µM) treatment induces apoptosis, we performed an assay that specifically stains apoptotic cells [24]. Fluorescent images of apoptotic cells stained by annexin V (Fig. 1, A-H) shows that 48 hours of MgCl₂ treatment significantly increased the number of apoptotic cells. This data confirms that apoptosis occurred in prostate cancer cells both with (LNCaP) and without (DU145, CL2, and PC3) androgen receptors.

![Figure 1](image1.png)

**Figure 1.** MgCl₂ induces apoptosis in prostate cancer cells. Prostate cancer cells LNCaP (A and B), DU145 (C and D), CL2 (E and F), and PC3 (G and H) control and after 48 hours of MgCl₂ treatment (500 µM) showing annexin V positive cells (arrows). Pictures acquired using Nikon Eclipse, GFP filter; n=3.

MgCl₂ Significantly Decreases the Cell Migration Speed.
We studied the impact of MgCl₂ on cell migration. Prostate cancer cell migration was evaluated by a monolayer wound scratch assay in control condition and after MgCl₂ (24 hours, 25 µM, 50 µM, 200 µM, 500 µM, and 1mM). The most effective concentration for all cells was 500 µM (Fig. 2) that decreased the migration speed of LNCaP by 34% (Fig. 2A), DU145 by 29% (Fig. 2B), CL2 by 23% (Fig. 2C), and PC3 (Fig. 2D) by 35%, compared to control. These results demonstrate that MgCl₂ impairs cell motility. Additionally, even at
Low concentrations MgCl₂ significantly reduced the migration speed of the highly metastatic cells (PC3) by 26%, 29%, 21%, 35%, and 32% at concentrations of 25, 50, 200, 500 µM, and 1 mM respectively (Fig. 2D).

**Figure 2.** MgCl₂ decreases significantly the migration speed in prostate cancer cells. LNCaP (A), DU145 (B), CL2 (C) and PC3 (D) control and after 24 hours of MgCl₂ treatment at specific concentrations: 25 µM, 50 µM, 200 µM, 500 µM, and 1mM. The speed was calculated from wound scratch assay pictures by subtracting the final wound gap from the initial (time 0); n=4. One way ANOVA tests: (A) LNCaP: control vs. 500 µM (p=<0.001) and 1mM (p=<0.001); (B) DU145: control vs. 25 µM (p=0.010), 50 µM (p=0.017), 200 µM (p=0.005), 500 µM (p=<0.001), and 1mM (p=0.022); (C) CL2: control vs. 25 µM, 200 µM, 500 µM, and 1mM (p=<0.001), 50 µM (p=0.009); (D) PC3: control vs. 25 µM, 50 µM, 200 µM, 500 µM, and 1mM; p=<0.001 all cases.

**MgCl₂ Decreases the Expression of V-H⁺-ATPase**

Highly metastatic tumors have at the plasma membrane a high expression and activity of V-H⁺-ATPase (proton pump) that act as the main regulator of membrane potential. This pump acidifies the extracellular environment that activates proteases to promote invasion and metastasis [25]. Due to this key function of proton pumps in cancer cells, we addressed whether MgCl₂ is able to decrease V-H⁺-ATPase expression in prostate cancer cells. Figure 3 shows the expression and quantification of V-H⁺-ATPase subunit c in LNCaP (Fig. 3A), DU145 (Fig. 3B), CL2 (Fig. 3C), and PC3 (Fig. 3D). MgCl₂ decreases the expression of V-H⁺-ATPase by more than 30% in all prostate cells.
**Figure 3.** MgCl₂ decreases the expression of V-H⁺-ATPase. V-H⁺-ATPase c subunit expression and quantification in prostate cancer cells: LNCaP (A), DU145 (B), CL2 (C), and PC3 (D), both control and after 48 hours of MgCl₂ treatment (500 µM); n=3. One-way ANOVA, *p=0.013.

**MgCl₂ increases F-actin and Myosin II (NMII)**

To understand the mechanism underlying the decrease in migration speed induced by MgCl₂ treatment in prostate cancer cells, we evaluated the expression of F-actin in both control and after MgCl₂ (500 µM) for 48 hours. Figure 4 shows F-actin staining in LNCaP (Figs. 4A, B), DU145 (Figs. 4C, D), CL2 (Figs. 4E, F), and PC3 (Figs. 4G, H). MgCl₂ significantly increases F-actin, which explains the decrease in migration speed, and also increases cell stiffness [26]. This increase in F-actin and cell stiffness promises a potential new therapeutic role of MgCl₂ for decreasing cell motility and suppressing metastasis. Figure 5 shows the fluorescence intensity of F-actin in prostate cancer cells control and after treatment with MgCl₂ (500 µM) for 48 hours. All prostate cancer cells LNCaP, DU145, CL2, and PC3 (Fig. 5) show significant increases in cortical F-actin induced by MgCl₂ treatment. NMII has a fundamental role in processes that require cellular reshaping and movement, such as cell adhesion, cell migration, and cell division [27, 28]. With these in mind, we evaluated the effect of MgCl₂ on NMII expression after 48 hours of treatment. Figure 6 shows the expression of NMII in prostate cancer cells control and after 48 hours of treatment with MgCl₂ (500 µM), LNCaP (6A), DU145 (6B), CL2 (6C), and PC3 (6D). DU145 after MgCl₂ treatment resulted in a significant decrease in NMII expression compared to control. However, LNCaP, CL2, and PC3 did not show significant decreases in NMII expression due to the differential expression after the MgCl₂ treatment. The levels of expression of NMII in CL2 were very low compared to all the other cells. CL2 is a LNCaP parental but without androgen receptors. These variations could lead to differential expressions of proteins in general.
**Figure 4.** MgCl₂ significantly increases the expression of cortical F-actin. F-actin fluorescence stain by phalloidin alexa fluor 488 in prostate cancer cells: control and after 48 hours of MgCl₂ treatment (500 µM). LNCaP control (A) and treated (B); DU145 control (C) and treated (D); CL2 control (E) and treated (F); and PC3 control (G) and treated (H); n=3, scale bar = 33 µM.

**Figure 5.** Increase of cortical F-actin induced by MgCl₂. Fluorescence intensity of F-actin: control and after 48 hours of MgCl₂ treatment (500 µM); n=85 cells analyzed. One way ANOVA, comparison between LNCaP control vs. MgCl₂ p=0.009, DU145 control vs. MgCl₂ p=<0.001, CL2 control vs. MgCl₂ p=0.0017, and PC3 control vs. MgCl₂ p=<0.001.
Figure 6. MgCl₂ decreases the expression of NMII in prostate cancer cells. NMIIIB expression and quantification in LNCaP (A), DU145 (B), CL2 (C), and PC3 (D), both control and after 48 hours of MgCl₂ treatment (500 µM); n=3. One way ANOVA, *p=0.05.

MgCl₂ Reverses the EMT by Decreasing Expression of Vimentin and Increasing Expression of E-cadherin

To address the mechanism of action of MgCl₂ we evaluated the expression of the EMT marker vimentin in prostate cancer cells LNCaP (Fig.7A), DU145 (Fig.7B), CL2 (Fig.7C), and PC3 (Fig.7D), in the control and after 48 hours of MgCl₂ treatment (500 µM). DU145 (Fig. 7B), with CL2 (Fig. 7C) demonstrating a significant decrease in vimentin expression after MgCl₂ treatment, showing a reversal of EMT caused by MgCl₂. We also evaluated the expression of another EMT marker, namely E-cadherin. E-cadherin is a common feature of epithelial cells, and in order to acquire a mesenchymal phenotype during EMT most tumor cells lose or decrease this protein expression [29]. MgCl₂ (500 µM) significantly increased the expression of E-cadherin for LNCaP (Fig. 8A), CL2 (Fig. 8C), and PC3 (Fig. 8D) but not for DU145 (Fig. 8B), which showed only an insignificant increase. These results revealed the role of MgCl₂ in EMT reversal in almost all cells evaluated. The E-cadherin expression difference observed may be due to the different tissue origins of these cells and presence or not of androgen receptors.
Figure 7. MgCl₂ decreases the expression of vimentin in prostate cancer cells, suggesting EMT reversal. Vimentin expression and quantification in LNCaP (A), DU145 (B), CL2 (C), and PC3 (D), both control and after 48 hours of MgCl₂ treatment (500 μM); n=3. One way ANOVA, **p=0.032, ***p=0.013.

Figure 8. MgCl₂ increases the expression of E-cadherin in prostate cancer cells suggesting EMT reversal. E-cadherin expression and quantification in LNCaP (A), DU145 (B), CL2 (C), and PC3 (D) - both control and after 48 hours of MgCl₂ treatment (500 μM); n=3. One way ANOVA, **p=0.006, ***p=0.008.
MgCl$_2$ Induces Chromatin Condensation and Decreases Transcription.

We also evaluated the nuclear changes induced by MgCl$_2$, in the control, and after 48 hours of MgCl$_2$ treatment (500 µM). Figure 9 shows the nucleus staining in LNCaP (Figs. 9A, B); DU145 (Figs. 9C, D); CL2 (Figs. 9E, F), and PC3 (Figs. 9G, H). The nucleus fluorescence stain increased significantly after the MgCl$_2$ treatment, reflecting a chromatin condensation effect of MgCl$_2$ [30]. Figure 10 shows the fluorescence intensity of nuclear stain DAPI in prostate cancer cells control and after MgCl$_2$ treatment. All prostate cancer cells LNCaP, DU145, CL2, and PC3 (Fig. 10) show a significant increase in nuclear brightness that indicates chromatin condensation induced by MgCl$_2$ treatment. In some cells, presence of bright spots are evident after treatment, indicating chromatin condensation (Fig. 10). After revealing that MgCl$_2$ induces chromatin condensation we also evaluated the expression of the transcription factor NFkB in prostate cancer cells during both the control and after MgCl$_2$ treatment to corroborate this result.

![Figure 9](image-url)

**Figure 9.** MgCl$_2$ increases chromatin condensation. Nuclear staining by DAPI in LNCaP (A and B), DU145 (C and D), CL2 (E and F), and PC3 (G and H), both control and after 48 hours of MgCl$_2$ treatment (500 µM); n=3, scale bar = 33 µM.

![Figure 10](image-url)

**Figure 10.** Increases in chromatin condensation induced by MgCl$_2$. Fluorescence intensity of nucleus (DAPI): control and after 48 hours of MgCl$_2$ treatment (500 µM); n=85 cells analyzed. One way ANOVA, comparison LNCaP control vs. MgCl$_2$ p=0.016, DU145 control vs. MgCl$_2$ p=<0.001, CL2 control vs. MgCl$_2$ p=<0.001, and PC3 control vs. MgCl$_2$ p=<0.001.
DISCUSSION

We believe we are the first study to show the beneficial effects of MgCl₂ (500 µM) on cell migration, V-H⁺-ATPase expression, and reversal of the EMT in prostate cancer. We find that MgCl₂ induces apoptosis of prostate cancer cells with androgen receptors (LNCaP) and without (CL2, DU145, and PC3). These results corroborate prior results showing induction of apoptosis by MgCl₂ in DU145 [2].

Following the cell viability degradation by MgCl₂, we addressed the possible effects of MgCl₂ on cell migration by measuring the migration speed of cells, both without and with treatment. We varied the concentration following a prior study [2] and selected the concentrations: 25, 50, 200, 500 µM, and 1 mM. However, 500 µM produced the maximal decrease (about 30%) in migration speed. Thus, MgCl₂ is not only able to induce apoptosis but also to decrease cell motility. Our data, showing a remarkable decrease in cell migration speed, encourage further studies, involving other cancer types and in vivo models, to fully establish MgCl₂’s role in suppressing metastasis.

V-H⁺-ATPase activation at the plasma membrane of tumor cells is known as a molecular marker for metastasis in human melanoma, pancreatic carcinoma, and breast cancer [9, 25, 31]. This pump is responsible for maintenance of pH that favors invasion and metastasis [9]. The extracellular acidification, caused by V-H⁺-ATPase extruding protons, activates secretion of proteases which facilitate degradation of the extracellular matrix and basement membrane and

Figure 11. MgCl₂ decreases the expression of transcription factor NFkB in prostate cancer cells. NFkB expression and quantification in LNCaP (A), DU145 (B), CL2 (C), and PC3 (D), both during control and after 48 hours of MgCl₂ treatment (500 µM); n=3. One way ANOVA, *p=0.012.
alters cytoskeleton structure. However, the role of cell mechanical properties during invasion remains unclear [32]. For the first time, we show that MgCl$_2$ decreases V-H$^+$-ATPase expression in prostate cancer cells with different metastatic potentials. V-H$^+$-ATPase c subunit expression is significantly reduced (by 30%) after MgCl$_2$ treatment. This result reinforces the potential therapeutic role of MgCl$_2$ targeting this pump that promotes invasion and metastasis.

A previous study demonstrated how an anticancer agent caused changes in morphology and F-actin distribution in leukemia cells [33]. This study is corroborated by our results showing that MgCl$_2$ induces significant changes in cortical F-actin in all prostate cancer cells. The fluorescence intensity of F-actin is shown to increase by MgCl$_2$ treatment. This F-actin increase suggests higher cell stiffness, which may explain the decrease in cell migration and resulting metastasis. It is known that cells sense the stiffness and spatial patterning of the microenvironment to modulate their own shape and cortical stiffness. However, the way substrate stiffness, cell shape, and cell stiffness affect each other is still unknown. It is clear how cell size and substrate stiffness can combine either to enhance or antagonize each other as well as affect cell morphology and mechanics [26]. Due to its effects on F-actin bundling and contractility, NMII acts as a key integrator of the processes that drive cell migration and adhesion. NMII is also an important end point on which many signaling pathways converge mainly through Rho GTPases [27, 28]. To address the other potential mechanical effects of MgCl$_2$, we evaluated the expression of NMII in prostate cancer cells control and after treatment with MgCl$_2$. We discovered MgCl$_2$ decreased significantly the expression of NMII in DU145.

Other studies demonstrated how epithelial mesenchymal transition (EMT) plays a critical role in malignant transformation and in cancer progression, in addition to providing invasive and metastatic properties to cancer cells. EMT is important in embryo development during which epithelial cells acquire mesenchymal and fibroblast-like phenotypes and show reduced intercellular adhesion and increased motility. Several oncogenic pathways such as peptide growth factors, Src, Ras, Wnt/β-catenin, and Notch induce EMT. A critical molecular event in this transition is the down-regulation of the cell adhesion molecule: E-cadherin [29]. MgCl$_2$ plays a crucial role in the EMT reversal in prostate cancer cells. The reversal occurs by decreasing the expression of the mesenchymal marker vimentin and by increasing the expression of the epithelial marker E-cadherin. We show how DU145 and CL2 significantly decreased the expression of vimentin while LNCaP, CL2, and PC3, while significantly increasing the expression of E-cadherin. These differences are possibly due to the differences in tissue origins that determine the physiological role of each cell line. Additionally, the sensitivity to androgen receptors could also cause these different trends observed. LNCaP is an androgen sensitive cell line; its derived CL2 clone is androgen receptor negative [34]. DU145, moderately metastatic and androgen receptor negative, was obtained from a brain metastasis [20]. PC3, also a highly metastatic cell line that does not express androgen receptors [21], was obtained from a bone metastasis [22].

We also find a significant increase in nuclear chromatin condensation with MgCl$_2$ treatment in all prostate cancer cells. This result corroborates previous studies that demonstrated that anticancer agents can induce chromatin condensation. Additionally, other studies have shown how chromatin is negatively charged, and as a result how the condensed state of nuclei and their chromatin depend on the cation concentration in the environment. Thus, a low concentration of
cations such as Mg$^{2+}$ leads to decondensation of chromatin and expansion of the nucleus, while the presence of Mg$^{2+}$ leads to chromatin condensation [35]. Since increased chromatin condensation can reduce cell transcription, we evaluated the expression of the transcription factor NFkB which is usually over-expressed in many cancer types. A prior study demonstrated how blockade of NFkB affected angiogenesis, growth, and metastasis of prostate cancer in mouse model. Thus, the reduced angiogenesis by blocking NFkB is the result of the inhibition of three important proangiogenic molecules: interleukin 8 (IL8), vascular endothelial growth factor (VEGF), and metalloproteinase 9 (MMP-9). Inhibition of NFkB activity in PC-3M cells also down regulated MMP-9 mRNA and collagenase activity, resulting in decreased invasion through matrigel [36]. Our data demonstrates how MgCl$_2$ decreased the expression of NFkB in prostate cancer cells, corroborating this previous study which revealed how inhibition of this transcription factor prevents cancer invasion, metastasis, and growth.

In summary, we evaluated the effect of MgCl$_2$ in prostate cancer cells which are lowly metastatic and sensitive to androgen receptor (LNCaP), moderately metastatic insensitive to androgen receptor (DU145), and highly metastatic insensitive to androgen receptor (CL2 and PC3). MgCl$_2$ induced morphological changes and apoptosis, reduced the migration speed, increased cortical F-actin, decreased NMII expression, increased chromatin condensation, decreased transcription factor NFkB expression, and caused EMT reversal (by reducing the expression of vimentin and by increasing the expressions of E-cadherin and F-actin). Future studies should explore the preventive and possible therapeutic role of MgCl$_2$ using in vivo studies as well as extending to other cancer types.

**CONCLUSIONS**

We evaluated the effect of MgCl$_2$ in prostate cancer cells which are non-tumorigenic and sensitive to androgen receptor (LNCaP), moderately metastatic insensitive to androgen receptor (DU145), and highly metastatic insensitive to androgen receptor (CL2 and PC3). MgCl$_2$ induced apoptosis, reduced the migration speed, increased cortical F-actin, decreased NMII expression, increased chromatin condensation, decreased transcription factor NFkB expression, and reversed EMT (by reducing the expression of vimentin and by increasing the expression of E-cadherin and F-actin). Future studies should explore the preventive and possible therapeutic roles of MgCl$_2$ in vivo and extending to other cancer types.

**Competing Interests:** The authors have no financial interests or conflicts of interest.

**Authors’ Contributions:** All authors contributed to this study.

**Acknowledgments:** We would like to thank Dr. Khan for reviewing our manuscript.

**Funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**REFERENCES**


31. Santos JM, Martinez-Zaguilan R, Facanha AR, Hussain F, Sennoune S. Vacuolar H-


